Immunohistochemistry News and Research

RSS

Immunohistochemistry (IHC) is an imaging technique to visualize antigens in cells. Labeled antibodies bind to target antigens in the cell to image the distribution and localization of specific proteins of interest

Transcription factor expression aids stage I lung cancer prognosis

Expression of thyroid transcription factor-1 is an independent predictor for recurrence of stage I lung adenocarcinoma and allows intermediate-grade tumors to be split into two prognostic subsets, scientists have found.

16 Nov 2012

UK scientists make breakthrough in new method of brain tumour diagnosis

UK scientists have made a breakthrough in a new method of brain tumour diagnosis, offering hope to tens of thousands of people.

20 Sep 2012

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.

13 Sep 2012

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

29 Aug 2012

S45F mutation may offer identifiable risk factor in recurrent pediatric aggressive fibromatosis

In the case of aggressive fibromatosis, the good news is that it is a slow-growing benign tumor. The bad news is that this abdominal tumor often recurs after surgical removal. This is particularly true among children. While headway has been made in isolating causes of this recurrence in adults, it is less clear in children.

23 Aug 2012

Folate, excision biomarkers not predictive for small-cell lung cancer response

Biomarkers associated with the folate metabolism and excision repair pathways are not sufficiently prognostic to aid chemotherapy decisions for patients with extensive-stage disease small-cell lung cancer, results of a phase III trial show.

8 Aug 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.

6 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID in determining the primary tumor site in high-grade, metastatic tumors. Results were reported at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Ventana Medical Systems, Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.

1 Jun 2012

New light on many biological differences between individual breast cancers

New findings presented at Europe's leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers.

4 May 2012

NeoGenomics first quarter revenue increases 72% to $15.2 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2012.

25 Apr 2012

Bimodal genes can define molecular subtypes of ovarian cancer

Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing.

9 Apr 2012

DBS introduces novel Multiplex Immunohistochemistry cancer kits

Diagnostic Biosystems, a specialty Immunohistochemistry company, announces its debut as an automated IHC company, introducing the Mosaic 360 System with a product offering of novel Multiplex Immunohistochemistry kits and a complementary line of optimized IHC reagents.

19 Mar 2012

Amylin may lead to severe heart damage in obese and diabetic patients

Severe heart damage in people who are obese and diabetic is linked with a pancreatic hormone called amylin, UC Davis researchers have found.

17 Feb 2012

Immunohistochemistry News and Research

Further Reading

Transcription factor expression aids stage I lung cancer prognosis

UK scientists make breakthrough in new method of brain tumour diagnosis

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

S45F mutation may offer identifiable risk factor in recurrent pediatric aggressive fibromatosis

Folate, excision biomarkers not predictive for small-cell lung cancer response

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

Kindstar, Insight Genetics collaborate to improve cancer care in China

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

New light on many biological differences between individual breast cancers

NeoGenomics first quarter revenue increases 72% to $15.2 million

Bimodal genes can define molecular subtypes of ovarian cancer

DBS introduces novel Multiplex Immunohistochemistry cancer kits

Amylin may lead to severe heart damage in obese and diabetic patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News